Capital Square LLC Has $707,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Capital Square LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 19.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 4,471 shares of the company’s stock after buying an additional 713 shares during the period. Capital Square LLC’s holdings in Johnson & Johnson were worth $707,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Christopher J. Hasenberg Inc acquired a new position in Johnson & Johnson in the first quarter valued at about $31,000. Keener Financial Planning LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. WFA Asset Management Corp grew its stake in Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at about $45,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $0.88 on Tuesday, hitting $150.12. The stock had a trading volume of 1,345,227 shares, compared to its average volume of 7,228,327. The stock has a market cap of $361.29 billion, a price-to-earnings ratio of 9.37, a price-to-earnings-growth ratio of 2.52 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business’s 50 day moving average is $147.95 and its two-hundred day moving average is $153.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the business posted $2.68 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.5 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Morgan Stanley cut their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, July 1st. Finally, HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.